IBDEI0CX ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5800,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5800,1,3,0)
 ;;=3^583.81
 ;;^UTILITY(U,$J,358.3,5800,1,4,0)
 ;;=4^SECONDARY GLOMERONEPHRITIS
 ;;^UTILITY(U,$J,358.3,5800,2)
 ;;=^82243
 ;;^UTILITY(U,$J,358.3,5801,0)
 ;;=583.9^^28^382^6
 ;;^UTILITY(U,$J,358.3,5801,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5801,1,3,0)
 ;;=3^583.9
 ;;^UTILITY(U,$J,358.3,5801,1,4,0)
 ;;=4^NEPHRITIS NOS
 ;;^UTILITY(U,$J,358.3,5801,2)
 ;;=^83446
 ;;^UTILITY(U,$J,358.3,5802,0)
 ;;=710.0^^28^382^17
 ;;^UTILITY(U,$J,358.3,5802,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5802,1,3,0)
 ;;=3^710.0
 ;;^UTILITY(U,$J,358.3,5802,1,4,0)
 ;;=4^SYSTEMIC LUPUS
 ;;^UTILITY(U,$J,358.3,5802,2)
 ;;=^72159^582.81
 ;;^UTILITY(U,$J,358.3,5803,0)
 ;;=582.89^^28^383^2
 ;;^UTILITY(U,$J,358.3,5803,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5803,1,3,0)
 ;;=3^582.89
 ;;^UTILITY(U,$J,358.3,5803,1,4,0)
 ;;=4^NEPHRITIS INTERSTITIAL,CHR
 ;;^UTILITY(U,$J,358.3,5803,2)
 ;;=^270349
 ;;^UTILITY(U,$J,358.3,5804,0)
 ;;=580.89^^28^383^1
 ;;^UTILITY(U,$J,358.3,5804,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5804,1,3,0)
 ;;=3^580.89
 ;;^UTILITY(U,$J,358.3,5804,1,4,0)
 ;;=4^NEPHRITIS INTERSTITIAL,AC
 ;;^UTILITY(U,$J,358.3,5804,2)
 ;;=^270340
 ;;^UTILITY(U,$J,358.3,5805,0)
 ;;=583.89^^28^383^3
 ;;^UTILITY(U,$J,358.3,5805,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5805,1,3,0)
 ;;=3^583.89
 ;;^UTILITY(U,$J,358.3,5805,1,4,0)
 ;;=4^NEPHROPATHY,ANALGESIC
 ;;^UTILITY(U,$J,358.3,5805,2)
 ;;=^83443
 ;;^UTILITY(U,$J,358.3,5806,0)
 ;;=042.^^28^384^1
 ;;^UTILITY(U,$J,358.3,5806,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5806,1,3,0)
 ;;=3^042.
 ;;^UTILITY(U,$J,358.3,5806,1,4,0)
 ;;=4^AIDS
 ;;^UTILITY(U,$J,358.3,5806,2)
 ;;=^266500
 ;;^UTILITY(U,$J,358.3,5807,0)
 ;;=581.1^^28^384^2
 ;;^UTILITY(U,$J,358.3,5807,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5807,1,3,0)
 ;;=3^581.1
 ;;^UTILITY(U,$J,358.3,5807,1,4,0)
 ;;=4^NEPHRITIS EPIMEMBRANOUS (FSGS)
 ;;^UTILITY(U,$J,358.3,5807,2)
 ;;=^270344
 ;;^UTILITY(U,$J,358.3,5808,0)
 ;;=581.2^^28^384^3
 ;;^UTILITY(U,$J,358.3,5808,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5808,1,3,0)
 ;;=3^581.2
 ;;^UTILITY(U,$J,358.3,5808,1,4,0)
 ;;=4^NEPHROSIS MEMBRANOPROL
 ;;^UTILITY(U,$J,358.3,5808,2)
 ;;=^270345
 ;;^UTILITY(U,$J,358.3,5809,0)
 ;;=581.3^^28^384^4
 ;;^UTILITY(U,$J,358.3,5809,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5809,1,3,0)
 ;;=3^581.3
 ;;^UTILITY(U,$J,358.3,5809,1,4,0)
 ;;=4^NEPHROSIS,MINIMAL CHANGE
 ;;^UTILITY(U,$J,358.3,5809,2)
 ;;=^82320
 ;;^UTILITY(U,$J,358.3,5810,0)
 ;;=581.9^^28^384^5
 ;;^UTILITY(U,$J,358.3,5810,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5810,1,3,0)
 ;;=3^581.9
 ;;^UTILITY(U,$J,358.3,5810,1,4,0)
 ;;=4^NEPHROTIC SYNDROME NOS
 ;;^UTILITY(U,$J,358.3,5810,2)
 ;;=^82357
 ;;^UTILITY(U,$J,358.3,5811,0)
 ;;=446.0^^28^384^6
 ;;^UTILITY(U,$J,358.3,5811,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5811,1,3,0)
 ;;=3^446.0
 ;;^UTILITY(U,$J,358.3,5811,1,4,0)
 ;;=4^POLYARTERITIS
 ;;^UTILITY(U,$J,358.3,5811,2)
 ;;=^91874
 ;;^UTILITY(U,$J,358.3,5812,0)
 ;;=581.81^^28^384^7
 ;;^UTILITY(U,$J,358.3,5812,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5812,1,3,0)
 ;;=3^581.81
 ;;^UTILITY(U,$J,358.3,5812,1,4,0)
 ;;=4^SECONDARY NEPHROTIC SYNDROME
 ;;^UTILITY(U,$J,358.3,5812,2)
 ;;=^270346
 ;;^UTILITY(U,$J,358.3,5813,0)
 ;;=710.0^^28^384^8
 ;;^UTILITY(U,$J,358.3,5813,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5813,1,3,0)
 ;;=3^710.0
 ;;^UTILITY(U,$J,358.3,5813,1,4,0)
 ;;=4^SYSTEMIC LUPUS
 ;;^UTILITY(U,$J,358.3,5813,2)
 ;;=^72159
 ;;^UTILITY(U,$J,358.3,5814,0)
 ;;=596.0^^28^385^1
 ;;^UTILITY(U,$J,358.3,5814,1,0)
 ;;=^358.31IA^4^2
 ;;
 ;;$END ROU IBDEI0CX
